Alexandra Maria Lazar

Dr. Alexandra Maria Lazar

Nuclear Medicine Department, Bucharest Oncological Institute "Alexandru Trestioreanu", Bucharest, Bucureşti, Romania
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MGMirela Gherghe
Mirela Gherghe
MMMario-Demian Mutuleanu
Mario-Demian Mutuleanu
ASAdina Elena Stanciu
Adina Elena Stanciu
IIIonela Nicoleta Irimescu
Ionela Nicoleta Irimescu
ALAlexandra Maria Lazar
Alexandra Maria Lazar
RARodica Maricela Anghel
Rodica Maricela Anghel
Purpose: To assess the potential added value of the SPECT-CT quantitative analysis in metastatic breast cancer lesions detection and differentiation from degenerative lesions. Methods: This prospective monocentric study was conducted on 70 female patients who underwent SPECT-CT bone scans using 99mTc–HDP that identified the presence of metastatic bone lesions and degenerative lesions in each patient. Once the lesions were identified, a quantitative analysis of radiotracer uptake was conducted. The highest one to five SUVmax values for both metastatic and degenerative bone lesions were identified in each patient and the data were then statistically analyzed. Results: The SUVmax value was significantly higher in metastatic bone lesions than in degenerative lesions (p < 0.001). The diagnostic accuracy of SPECT-CT quantitative data analysis revealed a sensitivity of 91.5% and a specificity of 93.3% at a cut-off value of the SUVmax of 16.6 g/mL. Conclusion: Quantitative analysis performed using SPECT-CT data can improve the diagnostic accuracy in differentiating between metastatic bone lesions and degenerative lesions, thus leading to appropriate treatment and better follow-up in metastatic breast cancer patients.

29 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MGMirela Gherghe
Mirela Gherghe
ALAlexandra Maria Lazar
Alexandra Maria Lazar
MMMario-Demian Mutuleanu
Mario-Demian Mutuleanu
CBCristian Ioan Bordea
Cristian Ioan Bordea
Sinziana IonescuSinziana Ionescu
Sinziana Ionescu
ASAdina Elena Stanciu
Adina Elena Stanciu
(1) Background: The aim of our study was to determine whether monitoring cardiac function through RNV and cardiac biomarkers could predict the cardiac impact of combined therapy with trastuzumab, pertuzumab and docetaxel, which are regularly used nowadays to treat HER2-positive breast cancer. (2) Methods: This prospective monocentric study included 22 patients, diagnosed with HER2-positive breast cancer, who had their LVEFs and cardiac biomarkers evaluated both at the beginning of their treatment and after 6 months. Among all of the enrolled patients, two blood specimens were collected to assess circulating cardiac biomarkers. RNV was performed in each patient after “in vivo” radiolabeling of the erythrocytes. The obtained results were then statistically correlated. (3) Results: The average LVEF decrease between the two time points was approximately 4%. Of the five biomarkers we considered in this paper, only NT-proBNP correlated with the LVEF values obtained both in the baseline study and after 6 months of follow-up (r = −0.615 for T0 and r = −0.751 for T1, respectively). ST2/IL-33R proved statistically significant at the T1 time point (r = −0.547). (4) Conclusions: A combination of LVEF, NT-proBNP and ST2/IL-33R assessment may be useful for early detection of cardiac impairment in breast cancer patients treated with trastuzumab, pertuzumab and docetaxel.

23 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MGMirela Gherghe
Mirela Gherghe
MMMario-Demian Mutuleanu
Mario-Demian Mutuleanu
ASAdina Elena Stanciu
Adina Elena Stanciu
IIIonela Nicoleta Irimescu
Ionela Nicoleta Irimescu
ALAlexandra Maria Lazar
Alexandra Maria Lazar
RARodica Maricela Anghel
Rodica Maricela Anghel
Background: Cancer represents the major cause of death mainly through its ability to spread to other organs, highlighting the importance of metastatic disease diagnosis and accurate follow up for treatment management purposes. Although until recently the main method for imaging interpretation was represented by qualitative methods, quantitative analysis of SPECT-CT data represents a viable, objective option. Methods: Seventy-five breast cancer patients presenting metastatic bone disease underwent at least two Bone SPECT-CT studies using [99mTc]-HDP between November 2019 to October 2022. Results: Our findings show a good positive relationship between the qualitative methods of imaging interpretation and quantitative analysis, with a correlation coefficient of 0.608 between qualitative whole body scintigraphy and quantitative SPECT-CT, and a correlation coefficient of 0.711 between the qualitative and quantitative interpretation of SPECT-CT data; nevertheless, there is a need for accurate, objective and reproducible methods for imaging interpretation, especially for research purposes. Conclusions: Quantitative evaluation of the SPECT-CT data has the potential to be the first choice of imaging interpretation for patient follow up and treatment response evaluation, especially for research purposes, because of its objectivity and expression of uptake changes in absolute units.

17 September 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MMMario-Demian Mutuleanu
Mario-Demian Mutuleanu
DPDiana Loreta Paun
Diana Loreta Paun
ALAlexandra Maria Lazar
Alexandra Maria Lazar
CPCristina Petroiu
Cristina Petroiu
OTOana Gabriela Trifanescu
Oana Gabriela Trifanescu
MGMirela Gherghe
Mirela Gherghe
(1) Background: Considering the importance that quantitative molecular imaging has gained and the need for objective and reproducible image interpretation, the aim of the present review is to emphasize the benefits of performing a quantitative interpretation of single photon emission computed tomography-computed tomography (SPECT-CT) studies compared to qualitative interpretation methods in bone lesion evaluations while suggesting new directions for research on this topic. (2) Methods: By conducting comprehensive literature research, we performed an analysis of published data regarding the use of quantitative and qualitative SPECT-CT in the evaluation of bone metastases. (3) Results: Several studies have evaluated the diagnostic accuracy of quantitative and qualitative SPECT-CT in differentiating between benign and metastatic bone lesions. We collected the sensitivity and specificity for both quantitative and qualitative SPECT-CT; their values ranged between 74–92% and 81–93% for quantitative bone SPECT-CT and between 60–100% and 41–100% for qualitative bone SPECT-CT. (4) Conclusions: Both qualitative and quantitative SPECT-CT present an increased potential for better differentiating between benign and metastatic bone lesions, with the latter offering additional objective information, thus increasing diagnostic accuracy and enabling the possibility of performing treatment response evaluation through accurate measurements.

31 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MGMirela Gherghe
Mirela Gherghe
ALAlexandra Maria Lazar
Alexandra Maria Lazar
ASAdina Elena Stanciu
Adina Elena Stanciu
MMMario-Demian Mutuleanu
Mario-Demian Mutuleanu
MSMaria-Carla Sterea
Maria-Carla Sterea
LGLaurentia Nicoleta Gales
Laurentia Nicoleta Gales
(1) Background: The aim of our study is to reveal the advantages and limitations of the use of 99mTcEDDA/HYNIC-TOC (Tektrotyd®, Polatom) in the diagnosis of gastroenteropancreatic neuroendocrine tumors and to compare our results with the values obtained for 111In-pentetreotide and 68Ga-DOTA-peptides, routinely used in medical practice. (2) Methods: This retrospective monocentric study included 173 patients with gastroenteropancreatic neuroendocrine tumors who underwent 99mTcEDDA/HYNIC-TOC scans as part of their clinical management. The examination protocol included a whole-body scan acquired 2 h after the radiotracer’s administration, with the SPECT/CT performed 4 h post-injection. Physiological and abnormal uptake were established by two experienced physicians and, based on the obtained results, sensitivity, specificity, accuracy, positive predictive value and negative predictive value were calculated. (3) Results: Our method presented a sensitivity of 90.5%, a specificity of 71.9%, and an accuracy of 84.3%, with a positive predictive value of 86.7% and a negative predictive value of 78.8%. (4) Conclusions: 99mTc-EDDA/HYNIC-TOC, a receptor-based radiopharmaceutical, could represent a competitor for 68Ga-labeled peptides in the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors. Our results show a lower sensitivity (90.5%) than 68Ga-DOTA-peptides, but with great specificity, accuracy, positive, and negative predictive values.

1 December 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMartina Sollini
Martina Sollini
CPCristiano Pini
Cristiano Pini
ALAlexandra Maria Lazar
Alexandra Maria Lazar
FGFabrizia Gelardi
Fabrizia Gelardi
GNGaia Ninatti
Gaia Ninatti
MKMargarita Kirienko
Margarita Kirienko
The capability of Large Language Models (LLMs) to support and facilitate research activities has sparked growing interest in their integration into scientific workflows. This paper aims to evaluate and compare against human researchers the performance of 6 different LLMs in conducting the various tasks necessary to produce a systematic literature review. The evaluation of the 6 LLMs was split into 3 tasks: literature search, article screening and selection (task 1); data extraction and analysis (task 2); final paper drafting (task 3). Their results were compared with a human-produced systematic review on the same topic, serving as reference standard. The evaluation was repeated on two rounds to evaluate between-version changes and improvements of LLMs over time. Out of the 18 scientific articles to be extracted from the literature for task 1, the best LLM managed to identify 13. Data extraction and analysis for task 2 was only partially accurate and cumbersome. The full papers generated by LLMs for task 3 were short and uninspiring, often not fully adhering to the standard PRISMA 2020 template for a systematic review. Currently, LLMs are not capable of conducting a scientific systematic review in the medical domain without prompt-engineering strategies. However, their capabilities are advancing rapidly, and, with an appropriate supervision they can provide valuable support throughout the review process.